NKGen Biotech Presents Troculeucel NK Cell Therapy at BIOCHINA 2026 Forum in Seoul

China's free-trade zone regulatory frameworks are drawing clinical-stage cell therapy developers into active partnership conversations, and NKGen Biotech is positioning troculeucel squarely inside that window. The company's Chairman and CEO, Paul Y. Song, M.D., is scheduled to present at the 2026 BIOCHINA Global Forum in Seoul, South Korea, on July 10, 2026, with a session focused on troculeucel's application in neurodegenerative diseases and the regulatory pathways that could support its commercialization in China.

For CDMOs and biopharma regulatory leads tracking China market entry, the presentation's scope is notable. Song will address specific free-trade zone policies that may allow assets currently in U.S. FDA Phase 2 clinical trials to advance toward commercialization in China, a pathway with direct implications for out-licensing structures, technology transfer agreements, and GMP-aligned manufacturing partnerships with Chinese CDMOs.

Troculeucel is an autologous, ex vivo expanded NK cell immunotherapeutic, assigned its International Nonproprietary Name by the World Health Organization, formerly designated SNK01. It is currently under evaluation in a Phase 2 trial for Alzheimer's disease. NKGen is also pursuing the program across amyotrophic lateral sclerosis, frontotemporal dementia, and Parkinson's disease, broadening the potential commercial and manufacturing scope for any future CDMO partner.

The BIOCHINA Global Forum functions as a structured partnering platform for cross-border business development in life sciences, making it a relevant venue for NKGen to engage Chinese pharmaceutical companies on development, manufacturing, and commercialization terms. The session runs July 10 at 13:40 KST within the Cell and Gene Therapy Innovations and R&D Collaboration track. Presentation materials will be posted to NKGen's website under Scientific Publications following the event.

For QA and regulatory leads evaluating cell therapy supply chains, the free-trade zone angle warrants close attention: China's Hainan and other designated zones have introduced accelerated review mechanisms for foreign-approved biologics, and understanding how a Phase 2 asset qualifies under those frameworks will be a prerequisite for any CDMO scoping a technology transfer or fill-finish arrangement tied to this program.

The measurable checkpoint ahead is whether NKGen converts BIOCHINA conversations into disclosed partnership or licensing agreements that specify manufacturing jurisdiction and GMP compliance obligations.

Source: NKGen Biotech via company press release, July 2, 2026.